Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 11393 - 11400 of 12007 results

Hidden Problems within Sabbaticals and Other Professional Leave Programs
May 15, 2012| Blog| Viewpoint

EB-5 Sunset Provision Unsettles Investors and Entrepreneurs
May 14, 2012| Blog| Viewpoint

gTLD Batching Update: Digital Archery Services Available at a Price
May 11, 2012| Blog| Viewpoint

NLRB's Plan: Expand labor's influence
May 9, 2012| Blog| Viewpoint

Arizona S.B. 1070’s Projected Impact
May 8, 2012| Blog| Viewpoint

Abbott Labs to Pay $1.6 Billion to Settle Consumer Protection and Misbranding Claims
May 8, 2012| Blog| Viewpoint

CMS, CCIO, and IRS Release Guidance Proposals on Employer Health Insurance Coverage
May 7, 2012| Blog| Viewpoint

Press Coverage Triggers HIPAA-Related Inquiry
May 7, 2012| Blog| Viewpoint
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|

Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|
